Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the addition of curcumin as an extra treatment for women with advanced cervical cancer receiving standard palliative radiotherapy. This open-label pilot trial aims to test whether combining curcumin with radiation is feasible, safe, and whether it improves treatment response. The study also examines how much curcumin is absorbed and how long it stays in the body, focusing on patients with FIGO stage IIIB to IVA cervical cancer. Participants will take 250 mg capsules of a specially formulated curcumin with enhanced bioavailability four times a day for 4 to 6 weeks, starting seven days before and continuing during the course of palliative radiotherapy. The radiotherapy treatment follows local guidelines, delivering a biologically effective dose of 45-55 Gy over three to five weeks. This combined treatment approach is being carefully monitored during the study period. During the trial, participants will provide blood and urine samples for lab tests and curcumin level measurements. They will undergo CT scans to assess tumor response and complete questionnaires to evaluate changes in quality of life. Researchers will measure treatment fidelity, objective response rate, disease control, adverse events, dose adjustments, and quality-of-life improvements over 13 to 17 weeks. The study includes safety monitoring and follow-up assessments lasting up to 14 weeks, with data collection continuing for about one year.
Actively Recruiting
This research investigates how tuberculosis TB infection affects the development and function of the placenta during pregnancy. It focuses on whether TB infection changes the structure or function of the placenta and if these changes contribute to pregnancy-related complications. The study is observational and includes pregnant women attending delivery clinics in Addis Abeba, Ethiopia, to better understand the impact of TB on maternal and infant health. Participants will be classified based on TB infection status using a blood-based interferon-gamma release assay QuantiFERON. The study involves collecting placental tissue after delivery for detailed examination, including histopathology, RNA and protein expression studies, and detection of TB bacteria. Blood samples and cord blood will also be collected for immune response and antibody analyses. Women with suspected active TB will undergo further diagnostic tests, including sputum sampling and chest X-rays. During the study, participants will provide information through electronic questionnaires about their medical and obstetric history. Physical assessments of mothers and infants will take place at birth and six weeks later. Placental samples will be processed and analyzed to identify pathological changes and molecular markers related to TB infection. The primary outcome is the presence of pathological placental findings, with secondary outcomes including placental gene and protein expression patterns and infant health outcomes. Participants will be followed up at six weeks postpartum for further evaluation and communication of test results.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an intervention to reduce non-communicable disease NCD risks among pregnant women attending routine antenatal care ANC in urban health centers across four Ethiopian cities. The study focuses on improving maternal health behaviors and pregnancy outcomes by addressing unhealthy diets, low physical activity, and air pollution exposure, factors linked to increased health risks for mothers and newborns and potential long-term NCD development. The trial compares two groups one receiving standard routine ANC and the other receiving structured lifestyle counseling integrated into ANC visits. This counseling targets diet, physical activity, and air pollution behaviors, supported by health worker training, facilitation by trained staff, and a digital ANC eRegistry for clinical decision support. The study is conducted in 77 urban health centers with about 1,268 pregnant women enrolled before 20 weeks gestation and followed through delivery. Participants attend routine ANC visits where data on birth weight and maternal behaviors are collected, alongside assessments of counseling quality and ANC service delivery. Additional biomarker studies analyze maternal and newborn samples for early NCD risk markers. Researchers monitor implementation feasibility and acceptability through surveys, routine data, and interviews. The total study duration covers pregnancy until delivery, with data collected at baseline, during pregnancy, and up to 18 months post-intervention for some measures.
Actively Recruiting
Healthy Volunteer
Researchers are studying the immune response in Ethiopian patients with cutaneous and visceral leishmaniasis to better identify human vaccine targets. This observational study evaluates six specific Leishmania antigens identified using a sensitive method called immunopeptidomics, comparing these to a standard soluble Leishmania antigen. The goal is to understand how T-cells respond before and after treatment and to support the development of a test for monitoring treatment. Participants include patients with suspected cutaneous or visceral leishmaniasis and healthy Ethiopian volunteers without prior infection. Blood and tissue samples such as lesions, bone marrow, or spleen will be stimulated outside the body to measure the release of interferon-gamma, indicating T-cell activation. Samples are collected at baseline and end of treatment for antigen screening, while the standard antigen is assessed at multiple timepoints. Additional analyses will explore T-cell characteristics and how responses vary across different genetic backgrounds. During the study, participants provide samples at specified times including before and after treatment. Researchers will analyze immune responses using various laboratory techniques such as flow cytometry and sequencing. The study will measure the presence and strength of T-cell responses, their functional profiles, and how these relate to treatment outcomes. Safety and consent are ensured, with healthy volunteers serving as controls to differentiate specific immune responses from general activation. The study runs from baseline to up to 28 days after treatment starts.
Actively Recruiting
Researchers are evaluating the use of thermotherapy TT as a treatment for cutaneous leishmaniasis CL in primary healthcare centers in the Sodo and South Sodo districts of Ethiopia. The study aims to determine whether using TT in these health centers is practical, acceptable, and suitable, as well as how effective TT is for treating CL in this setting. The project follows a phased approach, including training healthcare staff, piloting the intervention, and expanding treatment while assessing feasibility and cost-effectiveness. Thermotherapy treatment involves applying radio frequency-induced heat using the ThermoMed device, which heats the affected skin area to 50C for 30 seconds. Treatment may be administered up to twice based on patient response at four and eight weeks after the initial treatment. The study includes health centers that do not provide TT as a comparison group, where patients with CL are observed for up to three months before referral for thermotherapy. Participants receive training for diagnosis and management of CL and undergo assessments including digital photography and skin scraping for PCR confirmation. Patients treated with TT are monitored every four weeks up to 90 days for treatment response and again at 180 days to check for relapse. The study also evaluates the accuracy of healthcare staff in diagnosing CL and monitors treatment success, feasibility, acceptability, and adherence to training throughout the process. Total participation may last up to 180 days for treated patients.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the impact of switching from iron-folic acid supplementation IFA to multiple micronutrient supplementation MMS during pregnancy on newborn birthweight in Ethiopia. This program effectiveness study uses a two-arm cluster randomized trial to compare MMS to IFA as part of routine antenatal care. The study aims to provide evidence for the Ministry of Health of Ethiopia to guide large-scale implementation decisions and contribute to global knowledge on MMS effectiveness. The study involves districts randomized to either continue IFA supplementation or replace it with MMS, which includes 15 essential vitamins and minerals such as iron, vitamin A, vitamin D, and zinc. This trial runs for 42 months starting in March 2022, with birthweight data collected continuously from January 2023 to December 2024. Facility surveys to assess process, cost, acceptability, adherence, and implementation challenges will be conducted at baseline, midline, and endline. Participants include women aged 15 to 49 who deliver liveborn infants in enrolled health facilities across 42 districts in Ethiopia. Birthweight is measured routinely by trained midwives using digital scales. Additional data collection includes facility readiness, antenatal care details, costs, and interviews with staff and health care users. The primary outcome is mean birthweight, with secondary outcomes covering cost-effectiveness, adherence, and acceptability. The study concludes with primary analysis in April 2025.
Actively Recruiting
Chronic heart failure CHF is a long-term condition where the heart cannot pump blood effectively, leading to symptoms like shortness of breath, fatigue, leg swelling, and lowered ability to perform daily tasks. This trial evaluates if a mobile-based telemedicine program can improve the health-related quality of life for adult patients with CHF in Ethiopia by comparing it to routine care. The research focuses on patient-reported outcomes and aims to support cardiac care in resource-limited settings. The study involves 70 adult CHF patients divided into two groups 35 receive routine care plus an 8-week mobile-based telemedicine program, and 35 receive routine care only. The telemedicine program includes scheduled phone calls, text messages, and WhatsApp communications providing health education, medication reminders, lifestyle advice, and symptom monitoring. The control group continues with standard follow-up care without additional telemedicine support. Participants will have their quality of life measured at the start and after 8 weeks using the Minnesota Living with Heart Failure Questionnaire MLHFQ. Researchers will analyze changes in quality of life between the groups and may also assess self-care behaviors, medication adherence, and symptom control. The study runs from March to August 2026, with primary outcome assessment at 8 weeks and overall completion by August 21, 2026.
Actively Recruiting
Researchers are studying cutaneous leishmaniasis CL to better understand how miltefosine works in treating this skin condition. The study focuses on how the parasite clears from the body and how the drug is absorbed and distributed during treatment. This research aims to improve miltefosine dosing and treatment duration, especially for children and patients in Ethiopia, as current 28-day treatments may not be sufficient. The study observes two groups of patients one group weighing 30 kg or more will receive miltefosine based on weight 100 mg or 150 mg daily, while the other group, weighing less than 30 kg, will receive an allometric dose adjusted for weight, height, and sex. Treatment lasts a minimum of four weeks and can be extended up to eight weeks depending on response. The study will measure miltefosine concentrations in the blood and skin over time to understand drug levels and parasite dynamics. Participants will be closely monitored through blood and skin tests at multiple time points, from the start of treatment up to 180 days. Researchers will assess parasite levels, drug concentration, treatment outcomes, safety, and explore factors like resistance, nutritional status, and other infections that might affect treatment. Participants will provide informed consent and stay hospitalized during treatment. This detailed monitoring will help optimize dosing strategies for future patients.
Actively Recruiting
Plasmodium vivax malaria remains a challenge to elimination efforts due to its ability to form dormant liver stages called hypnozoites, which reactivate weeks to months after the initial infection causing relapses and continued transmission. These relapses contribute significantly to illness in affected individuals. Direct detection of hypnozoites is currently not possible, so researchers are evaluating an indirect approach using antibodies to specific P. vivax blood-stage antigens to identify recent infections within approximately the last 9 months. This trial compares two approaches in 48 clusters across Madagascar and Ethiopia. One group PvSeroTAT intervention will receive two rounds of serological testing at baseline and month 6 to detect recent P. vivax infections. Participants with positive antibody results and normal enzyme activity will be treated with primaquine for 7 or 14 days depending on location, alongside a three-day course of chloroquine or artesunate-amodiaquine. The control group will undergo similar testing but will not receive targeted treatment. Treatment adherence and side effects will be monitored during the first week after treatment. Participants are followed for 18 months with passive malaria case monitoring through health posts. Cross-sectional surveys at months 12 and 18 will measure P. vivax and P. falciparum prevalence using PCR testing. Outcomes include the proportion of individuals with detectable P. vivax infections after treatment rounds and the incidence of clinical malaria, as well as safety assessments like hemoglobin levels and adverse events. This study aims to assess the feasibility, acceptability, and effect of the PvSeroTAT strategy in reducing malaria relapses and transmission.
Actively Recruiting
This research aims to evaluate cardiac surgery outcomes for people with rheumatic heart disease RHD in Ethiopia, a low-income country. It compares the short- and long-term results of those who receive surgery with individuals who do not, due to limited access to cardiac surgery services. The study also examines the quality of anticoagulant therapy after surgery, assessing complications and treatment effectiveness compared to patients in Norway. The study observes three groups RHD patients undergoing cardiac surgery at Addis Abeba University Hospital, RHD patients who are not offered surgery, and Norwegian patients receiving anticoagulant therapy after valve replacement. Follow-up lasts 180 days for surgery outcomes, with ongoing monitoring of anticoagulation quality. Researchers look at mortality and complications such as heart failure, arrhythmias, thrombosis, bleeding, stroke, and infections. Participants will be monitored through clinical assessments and echocardiographic evaluations. The study tracks the time patients spend within therapeutic INR levels and records complications related to valve function and anticoagulant use. Outcome measures focus on short-term results at 180 days and longer-term anticoagulation quality. The study began in 2016 and will continue until 2026, involving matched control groups for comparison.
1-10 of 11
1